Kurome Therapeutics closes $15 million Series A financing

(CincyTech) The funding will support the pre-clinical advancement of dual IRAK1/4 and panFLT3 inhibitors to target cancer cells that evade the effects of both targeted therapy and chemotherapy drugs via adaptive resistance mechanisms, having co-opted IRAK1/4-mediated immune signaling pathways to survive.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news